BeiGene, Ltd. Files 8-K Report
Ticker: BEIGF · Form: 8-K · Filed: Oct 28, 2024 · CIK: 1651308
| Field | Detail |
|---|---|
| Company | Beigene, LTD. (BEIGF) |
| Form Type | 8-K |
| Filed Date | Oct 28, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
Related Tickers: BGNE
TL;DR
BeiGene filed an 8-K on 10/28 for events on 10/25. Details pending.
AI Summary
On October 25, 2024, BeiGene, Ltd. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific financial figures or material events detailed in the provided text. The report was filed on October 28, 2024.
Why It Matters
This 8-K filing indicates BeiGene, Ltd. is providing updates or submitting required documentation to the SEC, which could contain important operational or financial information for investors.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing header and does not contain specific material events or financial data that would indicate a high-risk situation.
Key Players & Entities
- BeiGene, Ltd. (company) — Registrant
- Mourant Governance Services (Cayman) Limited (company) — Agent for service of process
- October 25, 2024 (date) — Date of earliest event reported
- October 28, 2024 (date) — Date of report
FAQ
What specific "Other Events" are being reported by BeiGene, Ltd. in this 8-K filing?
The provided text does not specify the details of the "Other Events" beyond listing it as an item information category.
What "Financial Statements and Exhibits" are included with this 8-K filing?
The provided text lists "Financial Statements and Exhibits" as an item information category but does not detail their content.
What is the significance of the filing date (October 28, 2024) versus the date of the earliest event reported (October 25, 2024)?
The filing date is when the report was submitted to the SEC, while the date of the earliest event reported indicates the date on which the reported event(s) occurred.
What is BeiGene, Ltd.'s Standard Industrial Classification (SIC) code?
BeiGene, Ltd.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Where is BeiGene, Ltd.'s principal executive office located?
BeiGene, Ltd.'s principal executive offices are located at c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman KY1-1108, Cayman Islands.
Filing Stats: 548 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-10-28 06:05:24
Key Financial Figures
- $0.0001 — resenting 13 Ordinary Shares, par value $0.0001 per share BGNE The NASDAQ Global Sele
Filing Documents
- bgne-20241025.htm (8-K) — 34KB
- 0001651308-24-000139.txt ( ) — 154KB
- bgne-20241025.xsd (EX-101.SCH) — 2KB
- bgne-20241025_lab.xml (EX-101.LAB) — 21KB
- bgne-20241025_pre.xml (EX-101.PRE) — 12KB
- bgne-20241025_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. BeiGene, Ltd. (the "Company") is saddened to report that Mr. Donald W. Glazer, an independent director of the Company and the chair of the nominating and corporate governance committee of the board of directors (the "Board"), passed away recently. Mr. Glazer had been a member of the Board since 2013. The Company would like to express its sincere gratitude to Mr. Glazer for his invaluable contributions to the Company and extend its deepest condolences to his family.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL Exhibit Index Exhibit No. Description 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BEIGENE, LTD. Date: October 28, 2024 By: /s/ Chan Lee Name: Chan Lee Title: Senior Vice President, General Counsel